FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:417 July 28, 2005 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Van Assche, G. Related Article by Kleinschmidt-DeMasters, B.K. Related Article by Langer-Gould, A. PubMed Citation

In clinical trials, the term "patients at risk" refers to the altruistic people who volunteer to participate in studies of novel treatments. In this issue of the Journal, three reports^1,2,3 provide details about patients who were participating in trials involving experimental treatment with natalizumab for either multiple sclerosis or Crohn's disease and who were affected by progressive multifocal leukoencephalopathy (PML). PML is a rapidly progressive, often fatal demyelinating brain disorder caused by infection of the central nervous system with JC virus⁴; it usually occurs in patients with diminished T-cell function. These events remind us once again of the true . . . [Full Text of this Article]

Source Information

This editorial was published on June 9, 2005, at www.nejm.org.

Related Letters:

Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis
Berger T., Deisenhammer F., Álvarez-Cermeño J. C., Masjuan J., Villar L. M., Kleinschmidt-DeMasters B.K., Tyler K. L., Langer-Gould A., Atlas S. W., Pelletier D.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1744-1746, Oct 20, 2005. Correspondence

This article has been cited by other articles:

• Berger, T., Deisenhammer, F., Alvarez-Cermeno, J. C., Masjuan, J., Villar, L. M., Kleinschmidt-DeMasters, B.K., Tyler, K. L., Langer-Gould, A., Atlas, S. W., Pelletier, D. (2005). Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.. NEJM 353: 1744-1746 [Full Text]